Companies › JYAMS PET Research & Development
1 active drug program in 2 registered trials: 2 Phase 3; Neurology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| [18F]-APN-1607 Positron emission tomography (PET) imaging agent for detecting amyloid-beta pathology in A | APP | Phase 3 | Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia; Alzheimer's Disease | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07422857 | [18F]-APN-1607 | Phase 3 | Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia | Neurology | Dec 2026 |
| NCT07752784 | [18F]-APN-1607 | Phase 3 | Alzheimer's Disease | Neurology | Apr 2027 |
Alnylam Pharmaceuticals Roche Eli Lilly Eisai Acumen Pharmaceuticals Amyloid Solution HTA Nuravax
Bigespas Longboard Pharmaceuticals TriGemX Bio Zogenix ML Bio Solutions
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.